Cargando…
Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial
BACKGROUND: We previously conducted a Phase IIa randomized placebo-controlled trial of 40 subjects to assess the efficacy and safety of dupilumab use in those hospitalized with COVID-19 (NCT04920916). Based on our pre-clinical data suggesting downstream pulmonary dysfunction with COVID-19 induced ty...
Autores principales: | Hendrick, Jennifer, Ma, Jennie Z., Haughey, Heather M., Coleman, Rachael, Nayak, Uma, Kadl, Alexandra, Sturek, Jeffrey M., Jackson, Patrick, Young, Mary K., Allen, Judith E., Petri, William A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491385/ https://www.ncbi.nlm.nih.gov/pubmed/37693596 http://dx.doi.org/10.1101/2023.09.01.23293947 |
Ejemplares similares
-
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients with Moderate to Severe COVID 19: A Phase IIa Trial
por: Sasson, Jennifer, et al.
Publicado: (2022) -
Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial
por: Sasson, Jennifer, et al.
Publicado: (2022) -
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019) -
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
por: Zhang, Yihua, et al.
Publicado: (2021) -
Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
por: Jang, Dong Hyek, et al.
Publicado: (2020)